Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Tumor Angiogenesis Research

Executive Summary: Anlotinib hydrochloride (APExBIO, SKU C8688) is a novel small-molecule inhibitor targeting VEGFR2, PDGFRβ, and FGFR1, achieving IC₅₀ values of 5.6 ± 1.2 nM, 8.7 ± 3.4 nM, and 11.7 ± 4.1 nM, respectively (Xie et al., 2018). It exhibits high oral bioavailability and plasma protein binding, with a favorable safety profile in preclinical studies. Anlotinib inhibits VEGF/PDGF-BB/FGF-2-induced endothelial migration and tube formation, outperforming sunitinib, sorafenib, and nintedanib in comparative assays. Tissue distribution studies confirm strong accumulation in tumor and vascular tissues, supporting its application in anti-angiogenic and cancer research workflows (product page). The compound is not intended for diagnostic or medical use.

Biological Rationale

Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is essential for tumor growth and metastasis (Xie et al., 2018). Tumors exceeding 1 mm³ require angiogenesis to sustain proliferation. VEGF-driven signaling cascades, especially via VEGFR2, regulate endothelial cell migration, proliferation, and neovascularization. Inhibiting these pathways disrupts nutrient and oxygen supply to tumors, curbing their growth and invasiveness. Resistance in tumor cells to cytotoxic drugs is common, but endothelial cells remain genetically stable and less prone to acquired drug resistance (Xie et al., 2018). Thus, targeting endothelial tyrosine kinase signaling is a validated strategy for cancer research and anti-angiogenic drug development.

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride is a small-molecule inhibitor of three major receptor tyrosine kinases: VEGFR2 (IC₅₀ 5.6 ± 1.2 nM), PDGFRβ (8.7 ± 3.4 nM), and FGFR1 (11.7 ± 4.1 nM) (Xie et al., 2018, Table 1). It binds to the ATP-binding pocket of VEGFR2 with high affinity, blocking downstream ERK pathway activation. This prevents phosphorylation events critical for endothelial cell migration and tube formation. Anlotinib also suppresses PDGF-BB and FGF-2 mediated signaling, contributing to a broad-spectrum anti-angiogenic profile. In cell-based assays (e.g., EA.hy 926), it inhibits VEGF, PDGF-BB, and FGF-2 induced migration and capillary-like tube formation in a concentration-dependent manner. The compound does not directly inhibit tumor cell proliferation at sub-micromolar concentrations, highlighting its selectivity for endothelial cell processes (Xie et al., 2018, Fig. 2).

Evidence & Benchmarks

• Anlotinib exhibits an IC₅₀ of 5.6 ± 1.2 nM for VEGFR2 inhibition, outperforming sunitinib and sorafenib in comparative enzyme assays (Table 1).
• It effectively blocks VEGF-induced phosphorylation of ERK in HUVECs at picomolar concentrations (Figure 2C).
• Anlotinib inhibits endothelial cell migration and tube formation with high potency; these effects are dose-dependent and reproducible across multiple in vitro models (Figure 3A-B).
• In vivo, oral administration results in significant tumor vessel density reduction and, in some models, tumor regression, with superior efficacy to sunitinib (Figure 5A-D).
• Pharmacokinetic studies show oral bioavailability ranging from 28–77% (species-dependent) and extensive tissue distribution including lung, liver, kidney, heart, and tumor tissue (product page).
• LD₅₀ in 14-day oral administration in rats is 1735.9 mg/kg, indicating low acute toxicity (product page).

This article extends mechanistic insights found in Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inh... by providing updated quantitative benchmarks and evidence from comparative studies. For advanced troubleshooting and workflow strategies, see Anlotinib Hydrochloride: Optimizing Angiogenesis & Cancer...; this article clarifies optimal assay conditions and integration with ERK pathway readouts. In-depth mechanistic discussion is provided in Anlotinib Hydrochloride: Unraveling Multi-Target Angiogen..., while the present work adds latest pharmacokinetic and in vivo efficacy data.

Applications, Limits & Misconceptions

Anlotinib (hydrochloride) is primarily used in preclinical research to dissect angiogenic signaling and test anti-angiogenic strategies in cancer models. It is suitable for capillary tube formation assays, migration/invasion assays, and in vivo tumor xenograft models. The compound's high selectivity for endothelial cell processes makes it optimal for distinguishing anti-angiogenic from direct cytotoxic effects.

Common Pitfalls or Misconceptions

• Not a direct cytotoxic agent: At sub-micromolar concentrations, anlotinib does not significantly inhibit tumor cell proliferation in vitro; its primary effect is on endothelial cells (Xie et al., 2018).
• Not for diagnostic/clinical use: Anlotinib (hydrochloride) from APExBIO is for research use only and is not formulated for human or veterinary therapy (product page).
• Requires proper storage: The compound should be stored at -20°C to maintain stability.
• Metabolism-dependent clearance: CYP3A-mediated metabolism may vary across species and cell models, affecting in vivo results.
• Off-target effects at high doses: Concentrations above those required for VEGFR2/PDGFRβ/FGFR1 inhibition may affect additional kinases or cellular pathways.

Workflow Integration & Parameters

Anlotinib hydrochloride (C8688 kit, APExBIO) integrates seamlessly into angiogenesis and cancer research workflows. In endothelial cell migration and capillary tube formation assays, recommended starting concentrations are in the 1–100 nM range. For in vivo studies, oral administration protocols should be optimized for bioavailability (reference: 28–77% depending on species) and tissue distribution. The compound crosses the blood-brain barrier, supporting use in brain tumor models. It is compatible with ERK phosphorylation readouts and can be multiplexed with other pathway inhibitors for combinatorial screening. Ensure that all personnel observe safe handling and disposal practices as per institutional guidelines.

Conclusion & Outlook

Anlotinib hydrochloride is a validated, potent multi-target tyrosine kinase inhibitor for preclinical angiogenesis and cancer research. Its superior selectivity, bioavailability, and safety profile (as provided by APExBIO) make it a valuable asset for dissecting endothelial signaling and advancing anti-angiogenic drug discovery. Ongoing studies continue to expand its utility, including in models of resistance and combination therapies. For further information and ordering, refer to the Anlotinib (hydrochloride) product page.